FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:890-891 March 30, 1995 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Connor, E. M. PubMed Citation

To the Editor: Connor et al. (Nov. 3 issue)¹ report that a multicenter clinical trial, conducted in the United States and France, demonstrated a reduction in maternal–infant transmission of the human immunodeficiency virus type 1 (HIV-1) with zidovudine treatment. Planning is now under way for studies of perinatal zidovudine in several African, Asian, and South American countries. In an ideal world, implementing zidovudine regimens to reduce maternal–infant HIV transmission in developing nations would be humane and appropriate. But in the real world, is this approach practical?

Women in rural Africa often have little or no prenatal care, and identifying HIV-infected . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.